Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Aliada Therapeutics for $1.4 billion, gaining access to a phase I anti-amyloid antibody and a novel platform for efficient blood-brain barrier transport. Meanwhile, the FDA's accelerated approval program is facing setbacks as therapies for rare and neurological diseases earn accelerated approval but are later withdrawn from the market. Novartis has signed a potential $2.2 billion deal with Monte Rosa for molecular glue degraders targeting Vav1, while Biogen and Vertex have presented mid-stage readouts for iga nephropathy treatments. Analysts are optimistic about the potential of these treatments in the autoimmune disorder space. Sarepta's recent presentations on elevidys for Duchenne leave the community wanting more, while Revolution Medicines targets hard-to-treat pancreatic cancer with early-phase readouts. Iterum has won FDA approval for an oral UTI antibiotic and is seeking strategic transactions for the asset. Overall, new therapies are set to revolutionize treatment for genetic disorders like AATD.